Vanguard Group Inc Reata Pharmaceuticals Inc Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $5.59 Million - $7.44 Million	70,596 Added 2.57%	2,821,537 $288 Million
Q1 2023 May 15, 2023	BUY	$30.85 - $93.17 $1.4 Million - $4.22 Million	45,285 Added 1.67%	2,750,941 $250 Million
Q4 2022 Feb 10, 2023	BUY	$22.15 - $42.11 $1.16 Million - $2.2 Million	52,356 Added 1.97%	2,705,656 $103 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $657,804 - $1.24 Million	33,890 Added 1.29%	2,653,300 $66.7 Million
Q2 2022 Aug 12, 2022	SELL	$20.71 - $36.5 $490,247 - $864,028	-23,672 Reduced 0.9%	2,619,410 $79.6 Million
Q1 2022 May 13, 2022	BUY	$24.12 - $39.6 $2.06 Million - $3.38 Million	85,409 Added 3.34%	2,643,082 $86.6 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $440,056 - $1.91 Million	17,183 Added 0.68%	2,557,673 $67.4 Million
Q3 2021 Nov 12, 2021	BUY	$100.0 - $143.02 $193,000 - $276,028	1,930 Added 0.08%	2,540,490 $256 Million
Q2 2021 Aug 13, 2021	BUY	$78.27 - $151.29 $199 Million - $384 Million	2,538,560 New	2,538,560 $359 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.